Oestrogen + progestin

5 papers5 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

3 independent labs in 1 country

Funders: National Cancer Institute and 3 more

Humans4

Outcomes

Antithrombin

downin humans1

1 study

Oestrogen + progestin decreases antithrombin in humans (109% vs. 115%).
“In both user groups, antithrombin was lower than in non-users (109% for each vs. 115% in non-users, P < 0.001).”
Humanspost-menopausalfemalesn = 60
Post-menopausal hormone therapy and concentrations of protein C and antithrombin in elderly women
British journal of haematology1 Jul 2001

Associations

Lobular tumors

upin humans1OR 1.68

1 study

Oestrogen + progestin raises the risk of lobular tumors in humans (OR = 1.68 [95% CI 1.07-2.65]).
“and an association with lobular tumors (OR = 1.68 [95% CI 1.07-2.65])”
Humansdiagnosed with invasive breast cancerfemales
Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer
Breast cancer research and treatment29 Sep 2010

Poorly differentiated tumors

downin humans1OR 0.57

1 study

Oestrogen + progestin lowers the risk of poorly differentiated tumors in humans (OR = 0.57 [95% CI 0.38-0.85]).
“an inverse association with poorly differentiated tumors (OR = 0.57 [95% CI 0.38-0.85])”
Humansdiagnosed with invasive breast cancerfemales
Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer
Breast cancer research and treatment29 Sep 2010

Breast cancer-related mortality

downin humans1HR 0.45

1 study

Oestrogen + progestin lowers the risk of breast cancer-related mortality in humans (HR = 0.45 [95% CI 0.26-0.80]).
“Estrogen-progestin therapy (EPT) use was associated with a decreased risk of BCM (after adjustment for age, study, mammography, stage, and treatment), but only among older women”
Humansever use, diagnosed with invasive breast cancerfemales
Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer
Breast cancer research and treatment29 Sep 2010

Primary open-angle glaucoma

downin humans1

1 study

Oestrogen + progestin lowers the risk of primary open-angle glaucoma in humans (MVRR=0.58 (0.36 to 0.94)).
“current use of estrogen with progestin [MVRR=0.58 (0.36 to 0.94)] was associated with a reduced risk of POAG characterized by intraocular pressure >21 mm Hg before visual field loss”
Humanscharacterized by intraocular pressure >21 mm Hg before visual field loss, compared with never usefemales
Attributes of female reproductive aging and their relation to primary open-angle glaucoma: a prospective study
Journal of glaucoma1 Jan 2007